Xintela develops treatment for aggressive breast cancerLund, Sweden, June 17, 2020 - Xintela has decided that the company's next focus in it's oncology programme will be triple-negative breast cancer, which is an aggressive form of breast cancer that often metastasizes and has a poor prognosis. This decision was made based on the accumulated positive preclinical results using proprietary function blocking antibodies in cell experiments and in a validated tumor model. Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that accounts for 10-15% of all breast cancer diagnoses. It is far more aggressive than other breast cancer types due to a higher degree of metastases and a tendency to relapse following treatment. Aggressive cancers such as TNBC are a challenge for healthcare systems and there is an urgent need to find new, better targeted treatment strategies that will improve survival and the quality of life for these patients.
Xintela has previously announced positive preclinical results in glioblastoma, an aggressive brain tumor and that the company is evaluating other aggressive cancer types. Based on accumulated preclinical data showing that the company's integrin a10 antibodies inhibit TNBC cell function and reduce the growth of TNBC in a tumor model, Xintela has now decided to develop targeted treatment for TNBC. Xintela has previously filed a patent application covering the use of integrin a10 antibodies for the treatment of aggressive cancers including TNBC.
"The positive results further validate our patent-protected target molecule integrin a10b1 for the treatment of aggressive cancers and is another important milestone for the oncology programme and our subsidiary Targinta AB. In addition, we have identified an antibody that has the potential to become a successful product for the treatment of triple-negative breast cancer and other aggressive cancer types", says Xintela's CEO Evy Lundgren-Åkerlund.
This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication on the 17th of June 2020. Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: [email protected]
Medicon Village
223 81 Lund, Sweden
www.xintela.se
The following documents can be retrieved from beQuoted
2020-06-17-Behandling-brostcancer ENG.pdf About Xintela
Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, [email protected].
If you want to open the text in your webbrowser
click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected] beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.
Vi hoppas att Du uppskattar denna service.
| 